Möchten Sie immer auf dem neuesten Stand bleiben?

Châtillon, France, March 24, 2026 DBV Technologies to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review Changes went into effect on Monday, March 23, 2026 DBV...

Overview Full Year Research & Development Revenue of $19.7 Million; Q4 2025 Revenue of $3.8 MillionCash Rose to $15.4 Million at December 31, 2025 DALLAS, March 24, 2026 (GLOBE NEWSWIRE)...

MALVERN, Pa., March 24, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions,...

SUNNYVALE, Calif., March 24, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...

TORONTO, March 24, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the Fraser Health Authority has entered into a...

Laupheim (Germany), Milford, MA (USA), March 24, 2026 (GLOBE NEWSWIRE) -- Together We Build: Rentschler Biopharma celebrates Milford site progress and growth since U.S. expansion Milford,...

The Company signed a non-binding MOU with shareholders of Colugo. Colugo’s customer include the Israel Defense Forces, national first responders organizations and commercial companies Raanana,...

20/20 BioLabs Announces Exclusive U.S. License Agreement with ROKIT Healthcare

Preclinical data demonstrates leronlimab-mediated CCR5 inhibition enhances Temozolomide and radiation response in Glioblastoma  Leronlimab demonstrates synergy with standard-of-care therapies,...

Today, Biocartis announced that it has entered into a research collaboration with the Medical College of Wisconsin (MCW).